RxDoctor Payments Data

Aimee Bryant, APRN

Family · Kansas City, KSNPI 1518621887

Payments from drug & device makers

$1,037in general payments, 2019–2025

Across 44 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$222
  • AbbVie$198
  • Ardelyx, Inc.$127
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$85
  • Phathom Pharmaceuticals, Inc.$67
  • Janssen Scientific Affairs, LLC$57
  • plus $282 from 8 others

What the payments were for

  • Food & beverage$1,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,037 in reported general payments places this provider in the 70th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$35,781
Medicare patients
247
Services billed
614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase49$179,053
LinzessLinaclotide37$42,476
MotegrityPrucalopride Succinate18$15,151
Colestipol Hcl18$2,931
Lubiprostone14$1,944
Omeprazole114$1,867
Esomeprazole Magnesium29$1,766
Ondansetron Hcl20$1,659
Famotidine68$1,634
Dicyclomine Hcl37$1,439
Pantoprazole Sodium80$1,323
Ondansetron OdtOndansetron39$917
Promethazine Hcl24$576
Sucralfate12$527
Metoclopramide Hcl42$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$198$221,52986 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$43$15,15118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,579 family providers in Kansas.

Other family in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →